Entering text into the input field will update the search result below

Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q2 2022 Results - Earnings Call Transcript

Aug. 11, 2022 11:06 PM ETAchieve Life Sciences, Inc. (ACHV)
SA Transcripts profile picture
SA Transcripts

Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET

Company Participants

Cindy Jacobs - President, Chief Medical Officer & Director

Jerry Wan - Principal Accounting Officer

John Bencich - Chief Executive Officer

Conference Call Participants

Michael Higgins - Ladenburg Thalmann

François Brisebois - Oppenheimer

John Vandermosten - Zacks

Vernon Bernardino - H.C. Wainwright

Jim Molloy - Alliance Global Partners


Good day, ladies and gentlemen, and welcome to the Achieve Life Science Second Quarter 2022 Earnings Conference Call. [Operator Instructions] At this time, it is my pleasure to turn the floor over to your host, Nicole Jones [ph]. Nicole, the floor is yours.

Unidentified Company Representative

Thank you, operator, and thank you to everyone for joining the call. Today on the call from Achieve, we have John Bencich, Chief Executive Officer; Dr. Cindy Jacobs, President and Chief Medical Officer; and Jerry Wan, Principal Accounting Officer. Achieve management will be available for Q&A after the prepared remarks.

I’d like to remind everyone that today’s conference call contains forward-looking statements based on current expectations. These statements are only predictions, and actual results may vary materially from those projected. Please refer to Achieve documents available on the website and filed with the SEC concerning factors that could affect the company.

I’ll now turn the call over to John.

John Bencich

Thank you, Nicole, and thanks to everyone for joining us today. The second quarter of 2022 has been one of the most exciting yet for Achieve. Not only did we announce successful efficacy and safety results from our Phase III ORCA-2 trial in April, but we also received grant funding from the NIH, allowing us to proceed with the initiation of the Phase II ORCA-V1 trial in adult users of e-cigarettes. These were 2 major milestones for us to reach in the first

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.